

Letaplimab Biosimilar - Research Grade

Product Code: ICH5251

More Information

Species Reactivity: Human

Target: CD47

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Letaplimab Biosimilar - Research Grade

Antibodies against the same target: [Bulk Anti-Human CD47 \(B6H12\) Antibody \(ICH1014\)](#), [Anti-Mouse CD47 \(MIAP301\) In Vivo Antibody - Low Endotoxin \(ICH1282\)](#), [Lemzoparlimab Biosimilar - Research Grade \(ICH5034\)](#), [Magrolimab Biosimilar - Research Grade \(ICH5036\)](#), [Ligufalimab Biosimilar - Research Grade \(ICH5252\)](#), [Urabrelimab Biosimilar - Research Grade \(ICH5961\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q08722

Shipping Conditions: Blue ice

background: This product is an unconjugated, non-therapeutic recombinant analog of the anti-CD47 antibody letaplimab (IBI-188), built as a human IgG4-kappa immunoglobulin directed against human CD47 (UniProt Q08722). It is manufactured for research use only and is not the clinical drug; it is not intended for human or veterinary use. The analog is useful as a well-defined reagent for interrogating the CD47-SIRPalpha "don't eat me" axis in vitro and in preclinical settings, for example as a positive control or benchmarking tool in binding, blocking, and macrophage phagocytosis assays, in antibody-dependent cellular

phagocytosis (ADCP) and effector-function studies, and in ADC or bispecific development workflows where a defined CD47-targeting arm is needed. Because it shares the target specificity and IgG4 framework of the originator, it supports side-by-side comparison against novel candidates. It is supplied at research grade with low endotoxin (1 EU/mg; ultra-low 0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support scale-up, assay standardization, and reproducibility across experiments. CD47 (Q08722), also called integrin-associated protein (IAP), is a widely expressed five-transmembrane glycoprotein with a single N-terminal IgV-like extracellular domain. Its principal counter-receptor is signal regulatory protein alpha (SIRPalpha) on macrophages and other myeloid cells; CD47-SIRPalpha engagement delivers an inhibitory "don't eat me" signal that suppresses phagocytosis, allowing cells to be recognized as self. CD47 also binds thrombospondin-1 and associates in cis with integrins, contributing to cell adhesion, migration, and nitric-oxide signaling. Many tumors upregulate CD47 to evade macrophage-mediated clearance, which is why blocking the CD47-SIRPalpha interaction is a validated strategy to restore phagocytosis and enhance antigen presentation. Because CD47 is also expressed on erythrocytes, on-target binding to red cells is a well-recognized consideration in experimental design.

Other names: CD47, IAP, MER6, OA3, CD47 molecule, integrin associated protein

Specificity: Detects human CD47

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.



Delivery Time: 4 weeks